Honors & Awards


  • ASTRO Resident Recognition Award, American Society for Radiation Oncology (ASTRO) (2022)
  • NCCN 2022 Educational Grant, National Comprehensive Cancer Network (2022)
  • ASTRO Meeting Abstract Award and Travel Grant, American Society for Radiation Oncology (ASTRO) (2021)
  • Department of Medicine Award for Exceptional Service and Dedication during the COVID-19 Pandemic, Flushing Hospital Medical Center (2020)
  • Inductee, Gold Humanism Honor Society (2018)
  • Pilot Project Award, Lake Champlain Cancer Research Organization (2018)
  • President, UVM College of Medicine Student Council (2017-2019)
  • Annual Meeting Podium Presenter Travel Grant, Northern New England Clinical Oncology Society (2017)
  • Collaboration Research Grant, Northern New England Clinical Oncology Society (2017)
  • Exemplary Clinical Skills Award, UVM College of Medicine Foundations Awards (2017)
  • Vermont Medical Scholars Award, UVM College of Medicine (2016, 2017)
  • Annual Meeting Selection Committee Travel Award, Northern New England Clinical Oncology Society (2016)
  • Student-Led Research Grant, Northern New England Clinical Oncology Society (2016)
  • A & M Goran Scholar, UVM College of Medicine (2015-2019)
  • Chair of Student Leadership, UVM College of Medicine Student Council (2015-2019)
  • Winston Sargent Merit Medical Scholarship Recipient, UVM College of Medicine (2015)

Boards, Advisory Committees, Professional Organizations


  • Member, History Committee, American Society for Radiation Oncology (ASTRO) (2022 - Present)
  • Ex-Officio Member, Membership Committee, American Society for Radiation Oncology (ASTRO), (2022 - Present)
  • Member, ROCKET (Radiation Oncology Career Knowledge for Early Career Trainees) Presidential Task Force, American Radium Society (ARS) (2021 - Present)

Professional Education


  • Residency, Stanford University, Radiation Oncology (2024)
  • Internship, Flushing Hospital Medical Center, Internal Medicine (2020)
  • Medical Education, University of Vermont Larner College of Medicine, MD, Research Emphasis Track (2019)
  • Board Certification, Medical Dosimetrist Certification Board, CMD (2009)
  • Undergraduate Education, State University of New York Stonybrook, BS, Radiation Therapy (2006)

All Publications


  • Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical radiation oncology Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., Yi, E., Ko, R. B., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, M., Chin, A. L., Vitzthum, L. K. 2022

    Abstract

    Stereotactic ablative radiotherapy (SABR) results in high rates of primary tumor control for early-stage non-small cell lung cancer (NSCLC). For patients with isolated hilar or mediastinal nodal recurrences (INR) after SABR, the optimal salvage treatment strategy is unclear. The purpose of this study is to determine the rate of INR after SABR for early-stage NSCLC and to describe patterns of care and treatment outcomes after salvage therapy.This retrospective cohort study included 342 patients with Stage T1-3N0M0 NSCLC treated with definitive SABR from 2003-2018. We evaluated the incidence of INR and baseline factors between patients who did and did not experience INR. Among patients who experienced INR, we described treatment patterns and outcomes including overall (OS) and progression free survival (PFS) from the time of nodal failure using the Kaplan-Meier method.With a median follow-up of 3.3 years, the 3-year INR rate was 10.6% (6.6% -13.4%). Among the 34 patients experiencing INR, the 3-year rates of OS and PFS were 39.3% (24.4 - 63.3%) and 26.7% (14.1 - 50.3%), respectively. The 34 patients with INR were treated with RT alone (26.7 %), concurrent chemoradiotherapy (CRT) (43.3 %), chemotherapy alone (13.3%), or observation (16.7%). CRT had the best survival outcomes with a 3-year OS and PFS of 81.5% (61.1 - 100.0%) and 63.9% (40.7 - 100.0%), respectively. Of the patients treated with salvage RT or CRT, 14.3% experienced grade 3 toxicity with no patients having grade 4+ toxicity.INR occurred in approximately 10% of patients treated with SABR for early-stage NSCLC. The highest rates of OS an PFS among patients with INR were observed in those treated with salvage chemoradiotherapy.

    View details for DOI 10.1016/j.prro.2022.06.013

    View details for PubMedID 35858658

  • Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International journal of radiation oncology, biology, physics No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., Neal, J., Wakelee, H., Chin, A., Diehn, M., Loo, B. W., Chang, D. T., Pollom, E. L., Vitzthum, L. K. 2022

    Abstract

    Due to the limitations of current staging systems and evolving definitions, there are limited data on oligometastatic non-small cell lung cancer (NSCLC) epidemiology. The purpose of this study is to evaluate metastatic disease burden and the incidence of oligometastatic disease using recent clinical trial edibility criteria.A cohort of patients with metastatic NSCLC, diagnosed from 2016 to 2019, were randomly sampled from a curated tumor registry. Definitions for oligometastatic disease were obtained from relevant clinical trials. The Stanford Cancer Institute Research Database (SCIRDB) was used to identify baseline patient factors, systemic and local therapy, extent and location of metastatic lesions, and survival outcomes.Among 120 patients presenting with metastatic NSCLC, the majority had de novo metastatic disease (75%) with a median of 4 metastatic lesions involving 3 organ systems. 37.5% would have been eligible for at least one oligometastatic trial with 28.3% meeting criteria for MDACC, 20.0% for NRG-LU002, 6.7% for SINDAS and 16.7% for SABR-COMET. By adding malignant pleural effusions (MPE) and early progression as exclusionary criteria, only 54.1% of patients with ≤3 synchronous metastases were eligible for consideration of local therapy. Early progression on systemic therapy was associated with worse survival (10.0 vs. 42.4 months, p < 0.001), whereas presence of MPE was not. Of those tumors identified as oligometastatic, 44.4% received local therapy and 28.9% underwent ablative therapy to all sites. There was a trend towards greater overall survival (44.4 vs 24.9 months, p=0.055) and progression free survival (8.0 vs. 5.4 months, p=0.06) in patients meeting eligibility for at least one oligometastatic trial.Around 48% of patients with metastatic NSCLC had ≤3 metastases at presentation and 28% met clinical trial criteria for oligometastatic disease. Future research is needed to better define the oligometastatic state and identify patients most likely to benefit from local therapy.

    View details for DOI 10.1016/j.ijrobp.2022.04.050

    View details for PubMedID 35654305

  • Active Surveillance for Early Stage Lung Cancer. Clinical lung cancer Payne, R. G., Anker, C. J., Sprague, B. L., No, H. J., Lin, S. H., Lester-Coll, N. H. 2022

    Abstract

    OBJECTIVES: Data describing outcomes for patients with early stage lung cancer who undergo expectant management is lacking, despite evidence of a sub-population with indolent malignancies. We used the National Cancer Data Base (NCDB) to identify factors associated with active surveillance for early stage lung cancer. Additionally, we sought to describe outcomes of three different care plans: active surveillance, no treatment, and Stereotactic Body Radiation Therapy (SBRT).METHODS: Patients diagnosed in 2010 to 2017 with early stage lung cancer who underwent active surveillance, no treatment, and SBRT were retrospectively identified in the NCDB. Multinomial logistic regression was used to assess care plan selection. Kaplan Meier analysis was used to assess overall survival (OS).RESULTS: We identified 30,107 patients that met our inclusion criteria: 838 (3%) underwent active surveillance, 6388 patients (21%) received no treatment, and 22,881 (76%) underwent SBRT. Black race (relative risk ratio (RRR): 1.66) and older age (RRR: 1.02) were significant positive predictors of active surveillance selection. Conversely, higher tumor stage (RRR: 0.26) and squamous cell carcinoma (RRR: 0.35) were significant negative predictors of active surveillance selection. Kaplan Meier analysis revealed a longer median OS associated with active surveillance compared to no treatment at 49.3 months versus 26.5 months, respectively. SBRT OS was 43.1 months.CONCLUSIONS: We identified a population of lung cancer patients who underwent expectant management with favorable outcomes. Additionally, we identified factors associated with active surveillance selection. The selection of active surveillance over no treatment was associated with significantly longer OS.

    View details for DOI 10.1016/j.cllc.2022.01.001

    View details for PubMedID 35307270

  • Progression Versus Radiation Treatment Changes After Stereotactic Ablative Radiation Therapy of a Liver Metastasis PRACTICAL RADIATION ONCOLOGY No, H. J., Negrete, L. M., Pollom, E. L., Wakelee, H. A., Chang, D. T., Vitzthum, L. K. 2022; 12 (1): 1-2
  • FLASH Radiation Therapy Principles, Technology, and Clinical Translation AAMD 47th Annual Meeting No, H. J., Wu, Y. F., et al 2022
  • Validation of a Novel Cone-Less Set-up for Electron FLASH Radiation Delivery on a Clinical-Use Linear Accelerator Wu, Y. F., No, H. J., Manjappa, R., Skinner, L., Yu, S. J., Lau, B., Surucu, M., Schueler, E., Bush, K., Graves, E. E., Maxim, P. G., Loo, B. W. ELSEVIER SCIENCE INC. 2021: S139
  • Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., Neal, J. W., Ramchandran, K. J., Wakelee, H. A., Shaheen, S., Diehn, M., Chin, A. L., Loo, B. W., Vitzthum, L. ELSEVIER SCIENCE INC. 2021: E423
  • Feasibility of Clinically Practical Ultra-High Dose Rate (FLASH) Radiation Delivery by a Reversible Configuration of a Standard Clinical-Use Linear Accelerator No, H. J., Wu, Y. F., Manjappa, R., Skinner, L., Lau, B., Melemenidis, S., Yu, S. J., Surucu, M., Schueler, E., Bush, K., Graves, E. E., Maxim, P. G., Loo, B. W. ELSEVIER SCIENCE INC. 2021: S32
  • Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., Diehn, M., Chin, A., Vitzthum, L. LIPPINCOTT WILLIAMS & WILKINS. 2021: S105
  • Treatment Patterns for Isolated Nodal Recurrences in Non-Small Cell Lung Cancer After Definitive Stereotactic Ablative Radiotherapy No, H., Devine, M., Lau, B., Loo, B., Diehn, M., Chin, A., Vitzthum, L. LIPPINCOTT WILLIAMS & WILKINS. 2021: S109
  • Technological Basis for Clinical Trials in FLASH Radiation Therapy: A Review Applied Radiation Oncology Wu, Y., No, H. J., Breitkreutz, D. Y., Mascia, A. E., Moeckli, R., Bourhis, J., Schüler, E., Maxim, P. G., Loo Jr., B. W. 2021; 10 (2): 6-14
  • A Randomized Split-Body Feasibility Trial of Single-Fraction FLASH vs Conventional Electron Radiotherapy Using a Standard Clinical Linear Accelerator for Adults with Multi-Lesional Primary Cutaneous Lymphomas Flash Radiotherapy and Particle Therapy (FRPT) Conference Dworkin, M., No, H. J., et al 2021
  • Treatment Related Risk Factors for Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) No, H. J., Tam, M. M., Wu, P. ELSEVIER SCIENCE INC. 2020: 1214
  • Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly CUREUS No, H. J., Lester-Coll, N. H., Seward, D. J., Sidiropoulos, N., Gagne, H. M., Nelson, C. J., Garrison, G. W., Kinsey, C., Lin, S. H., Anker, C. J. 2018; 10 (10): e3472

    Abstract

    Objectives Treatment for stage IA lung cancer may be too aggressive an approach in elderly patients with competing co-morbidities. We report outcomes for those electing active surveillance (AS) and investigate factors that may predict indolent disease. Materials and methods Retrospective review was performed for 12 consecutive patients, ≥70 years old, with medically inoperable stage IA, T1N0M0 lung cancer and significant co-morbidities, who chose AS with radiation therapy (RT) reserved for clear disease progression. Collected data included Charlson-Deyo Comorbidity Index (CDCI) grades, histology, and tumor size changes. Volume doubling time (VDT) calculations used a modified Schwartz equation. Results Fifteen nodules underwent AS in 12 patients; three patients had more than one nodule. Median age of all patients was 78 (range, 71-85). All patients' CDCI grades were ≥1, 7 were ≥2. Eleven of 12 patients were deemed to be at high-risk for falls. Twelve nodules in 12 patients were biopsied; adenocarcinoma the prevailing common (47%) histology. The median, one, two and three year patient freedom-from-RT values were 21.4 months (95% CI: 11.6-not reached), 81%, 43%, and 29%, respectively. Median VDT of treated vs. untreated nodules was 189 days (range, 62-infinite) vs. 1153 days (range, 504-infinite), respectively. No patient progressed regionally or distantly, and there have been no cancer-related deaths. Due to cardiovascular events, two patients died and one remains on hospice. Median duration of AS for those still continuing computed tomography (CT) surveillance is 35.1 months. Conclusion Selected elderly patients with stage IA lung cancer and significant co-morbidities may undergo AS without detriment in outcome. Prospective AS studies are warranted.

    View details for DOI 10.7759/cureus.3472

    View details for Web of Science ID 000458694700011

    View details for PubMedID 30648024

    View details for PubMedCentralID PMC6318089

  • Effect of Tumor Volume Doubling Time on Prognosis for Stage I Non-small Cell Lung Cancers No, H., Gagne, H. M., Nelson, C. J., Kinsey, M., Garrison, G., Kikut, J., Gentchos, G., Seward, D., Sidiropoulos, N., Folefac, E., Leavitt, B., Ashikaga, T., Dragnev, K., Lin, S. H., Anker, C. J. ELSEVIER SCIENCE INC. 2017: E487
  • Active Surveillance for Elderly Stage IA Non-Small Cell Lung Cancer Patients No, H., Kikut, J., Garrison, G., Sidiropoulos, N., Leavitt, B., Gentchos, G., Lin, S. H., Anker, C. J. ELSEVIER SCIENCE INC. 2017: 232
  • Effect of Tumor Volume Doubling Time on Prognosis for Stage I Non-Small Cell Lung Cancers: An Update NNECOS Annual Meeting No, H. J., Seward, D., et al 2017
  • Breast, chest wall, and nodal irradiation with prone set-up: Results of a hypofractionated trial with a median follow-up of 35 months PRACTICAL RADIATION ONCOLOGY Shin, S., No, H., Vega, R., Fenton-Kerimian, M., Maisonet, O., Hitchen, C., DeWyngaert, J., Formenti, S. 2016; 6 (4): E81–E88

    Abstract

    To test clinical feasibility, safety, and toxicity of prone hypofractionated breast, chest wall, and nodal radiation therapy.Following either segmental or total mastectomy with axillary node dissection, patients were treated in an institutional review board-approved prospective trial of prone radiation therapy to the breast, chest wall, and supraclavicular and level III axillary lymph nodes. A dose of 40.5 Gy/15 fractions with a concomitant daily boost to the tumor bed of 0.5 Gy (total dose, 48 Gy) was prescribed. In postmastectomy patients, the same treatment was prescribed, but without a tumor bed boost. The primary endpoint was incidence of >grade 2 acute skin toxicity. The secondary endpoints were feasibility of treatment using prone set-up, compliance with protocol-defined dosimetric constraints, and incidence of late toxicity. A dosimetric comparison was performed between protocol plans (prone) and nonprotocol plans (supine), targeting the same treatment volumes.Sixty-nine patients with stage IB-IIIA breast cancer enrolled in this trial. Surgery was segmental mastectomy (n = 45), mastectomy (n = 23), and bilateral mastectomy (n = 1), resulting in 70 cases. None experienced >grade 2 acute skin toxicity according to the Common Terminology Criteria for Adverse Events, v 3.0, meeting our primary endpoint. Ninety-six percent of patients could be treated with this technique prone. However, 17 plans (24%) exceeded protocol constraints to the brachial plexus. Maximum long-term toxicity was 1 grade 2 arm lymphedema, 1 grade 3 breast retraction, and no occurrence of brachial plexopathy. Dosimetric comparison of protocol with nonprotocol plans demonstrated significantly decreased lung and heart doses in prone plans.Prone hypofractionated breast, chest wall, and nodal radiation therapy is safe and well tolerated in this study. Although the initial pattern of local and regional control is encouraging, longer follow-up is warranted for efficacy and late toxicity assessment, particularly to the brachial plexus.

    View details for DOI 10.1016/j.prro.2015.10.022

    View details for Web of Science ID 000378626600001

    View details for PubMedID 26723552

  • Anal Cancer Outcomes in Patients Treated With Intensity Modulated Compared to 3-Dimensional Radiation Therapy Cooper, B. T., Bitterman, D. S., Grew, D., No, H. S., Sanfilippo, N. J., Du, K. L. ELSEVIER SCIENCE INC. 2015: E165
  • Hypofractionated, Prone Accelerated Breast, and Nodal Irradiation: Results at a Median Follow-up of 33 Months Shin, S., No, H. S., Fenton-Kerimian, M. B., Maisonet, O. G., Hitchen, C., DeWyngaert, J. K., Formenti, S. C. ELSEVIER SCIENCE INC. 2015: E20
  • Dosimetric Comparison of Two Intensity Modulated Radiation Therapy Regimens in Patients with Head and Neck Cancer ASTRO Annual Meeting Shin, S. M., No, H. J., et al 2015
  • Dosimetric Comparison of Two Intensity Modulated Radiation Therapy Regimens in Patients with Nasopharyngeal Carcinoma LARS Conference Shin, S. M., McCarthy, A. K., No, H. J., et al 2015
  • Breast Cancer Radiation Therapy (RT) in Developing Countries: A Technique for Simple Prone Treatment Planning No, H. J., Galavis, P. E., Jozsef, G., Formenti, S. C. ELSEVIER SCIENCE INC. 2014: S262
  • Limits and Possibilities of a Simplistic Approach to Whole Breast Radiation Therapy Planning Hipp, E., Osa, E., No, H., Rosman, M., Formenti, S., Jozsef, G. WILEY. 2014: 312-+

    View details for DOI 10.1118/1.4888711

    View details for Web of Science ID 000436939600027

  • Limits and Possibilities of a Simplistic Approach to Whole Breast Radiation Therapy Planning Hipp, E., Osa, E., No, H., Rosman, M., Formenti, S., Jozsef, G. WILEY. 2014: 312
  • Reproducibility in Prone Breast Cancer Treatments AAMD Annual Meeting No, H. J., Coonce, M., et al 2014
  • Phase I/II Study of Prone Accelerated IMRT to Treat the Breast, Level 3 Axilla, and Supraclavicular Nodes Sethi, R. A., Jozsef, G., No, H., Goldberg, J. D., Formenti, S. C. ELSEVIER SCIENCE INC. 2012: S114
  • Comparison of three-dimensional versus intensity-modulated radiotherapy techniques to treat breast and axillary level III and supraclavicular nodes in a prone versus supine position RADIOTHERAPY AND ONCOLOGY Sethi, R. A., No, H., Jozsef, G., Ko, J. P., Formenti, S. C. 2012; 102 (1): 74–81

    Abstract

    To determine the optimal method of targeting breast and regional nodes in selected breast cancer patients after axillary dissection, we compared the results of IMRT versus no IMRT, and CT-informed versus clinically-placed fields, in supine and prone positions.Twelve consecutive breast cancer patients simulated both prone and supine provided the images for this study. Four techniques were used to target breast, level III axilla, and supraclavicular fossa in either position: a traditional three-field three-dimensional conformal radiotherapy (3DCRT) plan, a four-field 3DCRT plan using a posterior axillary boost field, and two techniques using a CT-informed target volume consisting of an optimized 3DCRT plan (CT-planned 3D) and an intensity-modulated radiotherapy (IMRT) plan. The prescribed dose was 50 Gy in 25 fractions.CT-planned 3D and IMRT techniques improved nodal PTV coverage. Supine, mean nodal PTV V50 was 50% (3-field), 59% (4-field), 92% (CT-planned 3D), and 94% (IMRT). Prone, V50 was 29% (3-field), 42% (4-field), 97% (CT-planned 3D), and 95% (IMRT). Prone positioning, compared to supine, and IMRT technique, compared to 3D, lowered ipsilateral lung V20.Traditional 3DCRT plans provide inadequate nodal coverage. Prone IMRT technique resulted in optimal target coverage and reduced ipsilateral lung V20.

    View details for DOI 10.1016/j.radonc.2011.09.008

    View details for Web of Science ID 000300654700013

    View details for PubMedID 21993404

  • IMRT versus Fixed-beam Technique for Regional Nodal Coverage in Breast Cancer Patients in a Prone versus Supine Treatment Position Sethi, R. A., No, H., Jozsef, G., Formenti, S. C. ELSEVIER SCIENCE INC. 2009: S203